Prit Kusirisin

Dr. Prit Kusirisin

Chiang Mai University, Chiang Mai, Thailand
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2020 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
Prit KusirisinPrit Kusirisin
Prit Kusirisin
SCSiriporn C. Chattipakorn
Siriporn C. Chattipakorn
NCNipon Chattipakorn
Nipon Chattipakorn
Contrast-induced nephropathy (CIN) or contrast-induced acute kidney injury (CI-AKI) is an iatrogenic acute kidney injury observed after intravascular administration of contrast media for intravascular diagnostic procedures or therapeutic angiographic intervention. High risk patients including those with chronic kidney disease (CKD), diabetes mellitus with impaired renal function, congestive heart failure, intraarterial intervention, higher volume of contrast, volume depletion, old age, multiple myeloma, hypertension, and hyperuricemia had increased prevalence of CIN. Although CIN is reversible by itself, some patients suffer this condition without renal recovery leading to CKD or even end-stage renal disease which required long term renal replacement therapy. In addition, both CIN and CKD have been associated with increasing of mortality. Three pathophysiological mechanisms have been proposed including direct tubular toxicity, intrarenal vasoconstriction, and excessive production of reactive oxygen species (ROS), all of which lead to impaired renal function. Reports from basic and clinical studies showing potential preventive strategies for CIN pathophysiology including low- or iso-osmolar contrast media are summarized and discussed. In addition, reports on pharmacological interventions to reduce ROS and attenuate CIN are summarized, highlighting potential for use in clinical practice. Understanding this contributory mechanism could pave ways to improve therapeutic strategies in combating CIN.

17 December 2025 in Critical Care Medicine
Verified
Journal Article
Closed access
Prit KusirisinPrit Kusirisin
Prit Kusirisin
ACAngela Corsaro
Angela Corsaro
JKJanice Y. Kung
Janice Y. Kung
OROleksa G. Rewa
Oleksa G. Rewa
MWM. Elizabeth Wilcox
M. Elizabeth Wilcox
SBSean M. Bagshaw
Sean M. Bagshaw
Objectives: Acute kidney injury (AKI) and delirium are common complications of critical illness. However, relatively few studies have evaluated their relationship. We conducted a systematic synthesis and meta-analysis of existing evidence to clarify this association in critically ill patients. Data Sources: A comprehensive search was conducted across MEDLINE, Embase, CINAHL, Scopus, Web of Science, and Cochrane Library for publications reporting both AKI and delirium in ICUs patients from January 2000 to January 2025. Study Selection: AKI was defined according to serum creatinine or urine output criteria based on the contemporary definitions used in the individual studies. The primary outcome was the proportion of critically ill patients with AKI who developed delirium. Secondary outcomes included mortality and health service utilization. Data Extraction: Pooled meta-analyses were summarized as effect sizes in proportions, risk ratios (RRs), odds ratios, or weighted mean differences (WMDs) using a random-effects model. The certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation approach. Data Synthesis: Eighteen observational studies comprising 158,694 patients were included. Overall study quality was moderate. The pooled proportion of delirium among patients with AKI was 32% (95% CI, 18–47%). Delirium was associated with higher mortality (RR, 2.36; 95% CI, 1.61–3.47; moderate certainty), greater renal replacement therapy use (RR, 3.12; 95% CI, 1.89–5.15; moderate certainty), longer ICU stays (WMD, 3.54 d; 95% CI, 1.20–5.87 d; moderate certainty), and longer hospital stays (WMD, 4.78 d; 95% CI, 3.48–6.09 d; moderate certainty) compared with patients with AKI not experiencing delirium. Conclusions: Delirium is common among critically ill patients with AKI and is associated with worse outcomes and greater health resource use.

2 November 2023 in Blood Purification
Verified
Journal Article
Closed access
PDF file
Prit KusirisinPrit Kusirisin
Prit Kusirisin
KNKajohnsak Noppakun
Kajohnsak Noppakun
KTKonlawij Trongtrakul
Konlawij Trongtrakul
SVSurachet Vongsanim
Surachet Vongsanim
YSYuttitham Suteeka
Yuttitham Suteeka
NSNattachai Srisawat
Nattachai Srisawat
Introduction: Severe COVID-19 pneumonia can activate a cytokine storm. Hemoperfusion can reduce pro-inflammatory cytokines in sepsis but is still debated in the COVID-19 setting. Thus, we sought to investigate the benefits of HA-330 cytokine adsorption through clinical and laboratory outcomes. Methods: We conducted a single-center prospective observational study in adults with severe COVID-19 pneumonia admitted to the intensive care unit at Chiang Mai University Hospital (Chiang Mai, Thailand). Those with cytokine storms indicated by organ injury, including acute respiratory distress syndrome (ARDS), and high inflammatory markers were included. Patients treated with the HA-330 device were classified as a hemoperfusion group, while those without cytokine adsorption were classified as a control group. We compared the outcomes on day 7 after treatment and evaluated the factors associated with 60-day mortality. Results: A total of 112 patients were enrolled. Thirty-eight patients received hemoperfusion, while 74 patients did not. Baseline cytokine storm parameters were comparable. In univariate analysis, there was an improvement in clinical and laboratory effects from hemoperfusion therapy. In multivariate analysis, APACHE II score, SOFA score, PaO2/FiO2, the number of hemoperfusion sessions, the amount of blood purified, high-sensitivity C-reactive protein, and IL-6 were associated with mortality. Using at least 3 sessions of hemoperfusion could mitigate, the 60-day mortality (adjusted odds ratio 0.25, 95% confidence interval: 0.03–0.33, p = 0.001). By categorizing the amount of blood treated into 3 groups of <1 L/kg, 1–2 L/kg, and ≥2 L/kg, there was a linear dose-response association with survival, which was better in the higher volume purified (mortality 60% vs. 33.3% vs. 0%, respectively, p = 0.015). Conclusions: The early initiation of HA-330 hemoperfusion could improve the severity score and laboratory outcomes of COVID-19 ARDS. The optimal dose of at least three sessions or the amount of blood purified greater than 1 L/kg was associated with a reduction in 60-day mortality.

30 March 2022 in Seminars in Dialysis
Verified
Journal Article
Closed access
Prit KusirisinPrit Kusirisin
Prit Kusirisin
NSNattachai Srisawat
Nattachai Srisawat

21 April 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
PKPimpisid Koonyosying
Pimpisid Koonyosying
WKWinthana Kusirisin
Winthana Kusirisin
Prit KusirisinPrit Kusirisin
Prit Kusirisin
BKBoonsong Kasempitakpong
Boonsong Kasempitakpong
NSNipon Sermpanich
Nipon Sermpanich
NPNarisara Paradee
Narisara Paradee
This study aimed to develop perilla fruit oil (PFO)-fortified soybean milk (PFO-SM), identify its sensory acceptability, and evaluate its health outcomes. Our PFO-SM product was pasteurized, analyzed for its nutritional value, and had its acceptability assessed by an experienced and trained descriptive panel (n = 100) based on a relevant set of sensory attributes. A randomized clinical trial was conducted involving healthy subjects who were assigned to consume deionized water (DI), SM, PFO-SM, or black sesame-soybean milk (BS-SM) (n = 48 each, 180 mL/serving) daily for 30 d. Accordingly, health indices and analyzed blood biomarkers were recorded. Consequently, 1% PFO-SM (1.26 mg ALA rich) was generally associated with very high scores for overall acceptance, color, flavor, odor, taste, texture, and sweetness. We observed that PFO-SM lowered levels of serum triglycerides and erythrocyte reactive oxygen species, but increased phagocytosis and serum antioxidant activity (p < 0.05) when compared to SM and BS-SM. These findings indicate that PFO supplementation in soybean milk could enhance radical-scavenging and phagocytotic abilities in the blood of healthy persons. In this regard, it was determined to be more efficient than black sesame supplementation. We are now better positioned to recommend the consumption of PFO-SM drink for the reduction of many chronic diseases. Randomized clinical trial registration (Reference number 41389) by IRSCTN Registry.

23 March 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
PNPhoom Narongkiatikhun
Phoom Narongkiatikhun
KNKajohnsak Noppakun
Kajohnsak Noppakun
RCRomanee Chaiwarith
Romanee Chaiwarith
PWPORAMED WINICHAKOON
PORAMED WINICHAKOON
SVSurachet Vongsanim
Surachet Vongsanim
VOVuddhidej Ophascharoensuk
Vuddhidej Ophascharoensuk
Background: Vaccines that prevent SARS-CoV-2 infection are considered the most promising approach to modulating the pandemic. There is scarce evidence on the efficacy and safety of different vaccine prime-boost combinations in MHD patients since most clinical trials have used homologous mRNA vaccine regimens. Methods: This prospective observational study assessed the immunogenicity and safety of homologous CoronaVac® (SV-SV), ChAdOx1 nCoV-19 (AZD1222) (AZ-AZ), and the heterologous prime-boost of SV-AZ, among MHD patients. Results: A total of 130 MHD participants were recruited. On day 28, after the second dose, seroconversion results of the surrogate virus neutralization test were not different between vaccine regimens. The magnitude of the receptor-binding domain-specific IgG was highest among the SV-AZ. Different vaccine regimens had a distinct impact on seroconversion, for which the heterologous vaccine regimen demonstrated a higher probability of seroconversion (OR 10.12; p = 0.020, and OR 1.81; p = 0.437 for SV-AZ vs. SV-SV, and SV-AZ vs. AZ-AZ, respectively). There were no serious adverse events reported in any of the vaccine groups. Conclusions: Immunization with SV-SV, AZ-AZ, and SV-AZ could generate humoral immunity without any serious adverse events among MHD patients. Using the heterologous vaccine prime-boost seemed to be more efficacious in terms of inducing immunogenicity.